Search

Your search keyword '"McClure, Matt"' showing total 26 results

Search Constraints

Start Over You searched for: Author "McClure, Matt" Remove constraint Author: "McClure, Matt"
26 results on '"McClure, Matt"'

Search Results

1. WED-361 Dosing with the Capsid Assembly Modulator ALG-000184 in Untreated HBeAg Negative CHB Subjects Results in Potent Antiviral Effects Including Suppression of HBV DNA/RNA and Declines in HBcrAg Levels

2. Treatment for up to 24 weeks with the capsid assembly modulator ALG-000184 results in dose related reductions in HBsAg in subjects with HBeAg positive chronic hepatitis B

3. ALG-000184, a capsid assembly modulator, dosed with entecavir for up to 28 weeks is well tolerated and resulted in substantial declines in surface antigen levels in untreated Hepatitis B e antigen positive subjects with chronic hepatitis B

4. Pharmacodynamic durability of ALG-125755, a GalNAc-conjugated siRNA, correlated with total and RNA induced complex (RISC) bound siRNA in mouse liver

5. Getting It Right: Aligning Technology Initiatives for Measurable Student Results. The 21st Century Fluency Series

6. Safety, tolerability and pharmacokinetics of single ascending doses of ALG-020572, a GalNAc-conjugated antisense oligonucleotide, in healthy subjects

7. Safety and pharmacokinetics (PK) of single and multiple ascending oral doses of ALG-055009, a thyroid hormone receptor beta agonist for the treatment of non-alcoholic steatohepatitis (NASH), in healthy volunteers and subjects with hyperlipidemia

8. Safety, pharmacokinetics, and antiviral activity of the class II capsid assembly modulator ALG-000184 in subjects with chronic hepatitis B

9. Safety, pharmacokinetics, and antiviral activity of the S-antigen Transport Inhibiting Oligonucleotide Polymers (STOPS) drug candidate ALG-010133 in subjects with chronic hepatitis B

11. WED-365 Extended treatment of HBeAg+ CHB subjects with the Capsid assembly modulator ALG-000184 with or without Entecavir is associated with reductions in viral markers and favorable anti-HBeAb trends

12. Corrigendum to 'Relationships between metabolic profiles and gene expression in liver and leukocytes of dairy cows in early lactation' (J. Dairy Sci. 104:3596–3616)

13. Corrigendum to “Relationships between metabolic profiles and gene expression in liver and leukocytes of dairy cows in early lactation” (J. Dairy Sci. 104:3596–3616)

14. Genome‐wide association for milk production and lactation curve parameters in Holstein dairy cows

15. Potential of milk mid-infrared spectra to predict nitrogen use efficiency of individual dairy cows in early lactation

16. SAT-192 - Treatment for up to 24 weeks with the capsid assembly modulator ALG-000184 results in dose related reductions in HBsAg in subjects with HBeAg positive chronic hepatitis B

18. LBP-18 - ALG-000184, a capsid assembly modulator, dosed with entecavir for up to 28 weeks is well tolerated and resulted in substantial declines in surface antigen levels in untreated Hepatitis B e antigen positive subjects with chronic hepatitis B

21. Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa

22. MUX: View from the Top 2020.

23. Chefs’ FARMERS’ MARKET TIPS.

24. Positive Experience in Rural Arkansas.

25. Whatever It Takes.

26. No major pay hikes for teachers in Alberta budget.

Catalog

Books, media, physical & digital resources